文献速递肾小球疾病

Iptacopan治疗IgA肾病的随机双盲安慰剂对照2期研究结果

Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy.
PubMed 文献 · Kidney Int · 2023-10-31

该随机双盲平行组适应性2期研究纳入活检确诊的IgA肾病患者,评估四种剂量iptacopan(10、50、100、200 mg bid)与安慰剂对照。主要分析显示3个月时24小时UPCR存在显著剂量反应效应,200 mg bid组UPCR降低23%(80%CI 8-34%)。Iptacopan耐受良好,支持进一步开展3期试验。

要点

  • Iptacopan 200 mg bid治疗3个月使UPCR降低23%(80%CI 8-34%),呈显著剂量反应效应。
  • 100和200 mg组UPCR至6个月进一步下降,200 mg组从基线均值1.3 g/g降至0.8 g/g。
  • Iptacopan耐受良好,无死亡、治疗相关严重不良事件或细菌感染报告。

核心结论

  • Iptacopan在IgA肾病患者中产生显著剂量依赖的UPCR降低,并持续抑制替代补体途径活性。

研究设计与样本

  • 随机双盲平行组适应性2期研究(NCT03373461),纳入活检确诊的IgA肾病患者。
  • 患者随机接受iptacopan 10、50、100或200 mg bid或安慰剂,Part 1治疗3个月(46例),Part 2治疗6个月(66例)。

主要发现

  • 3个月时iptacopan 200 mg bid组UPCR降低23%(80%CI 8-34%),呈统计学显著剂量反应效应。
  • 200 mg组UPCR从基线均值1.3 g/g降至6个月时0.8 g/g。
  • 观察到血浆Bb、血清Wieslab和尿C5b-9等补体生物标志物水平持续降低。
  • iptacopan耐受良好,无死亡、治疗相关严重不良事件或细菌感染报告。

临床怎么用

  • 研究结果支持iptacopan在正在进行的3期试验(APPLAUSE-IgAN;NCT04578834)中进一步评估。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Targeting the alternative complement pathway is an attractive therapeutic strategy given its role in the pathogenesis of immunoglobulin A nephropathy (IgAN). Iptacopan (LNP023) is an oral, proximal alternative complement inhibitor that specifically binds to Factor B. Our randomized, double-blind, parallel-group adaptive Phase 2 study (NCT03373461) enrolled patients with biopsy-confirmed IgAN (within previous three years) with estimated glomerular filtration rates of 30 mL/min/1.73 m2 and over and urine protein 0.75 g/24 hours and over on stable doses of renin angiotensin system inhibitors. Patients were randomized to four iptacopan doses (10, 50, 100, or 200 mg bid) or placebo for either a three-month (Part 1; 46 patients) or a six-month (Part 2; 66 patients) treatment period. The primary analysis evaluated the dose-response relationship of iptacopan versus placebo on 24-hour urine protein-to-creatinine ratio (UPCR) at three months. Other efficacy, safety and biomarker parameters were assessed. Baseline characteristics were generally well-balanced across treatment arms. There was a statistically significant dose-response effect, with 23% reduction in UPCR achieved with iptacopan 200 mg bid (80% confidence interval 8-34%) at three months. UPCR decreased further through six months in iptacopan 100 and 200 mg arms (from a mean of 1.3 g/g at baseline to 0.8 g/g at six months in the 200 mg arm). A sustained reduction in complement biomarker levels including plasma Bb, serum Wieslab, and urinary C5b-9 was observed. Iptacopan was well-tolerated, with no reports of deaths, treatment-related serious adverse events or bacterial infections, and led to strong inhibition of alternative complement pathway activity and persistent proteinuria reduction in patients with IgAN. Thus, our findings support further evaluation of iptacopan in the ongoing Phase 3 trial (APPLAUSE-IgAN; NCT04578834).

来源:Kidney Int,查看原文。版权归原作者所有。

引用

  1. Zhang H, Rizk DV, Perkovic V, et al. Results of a randomized double-blind placebo-controlled Phase 2 study propose iptacopan as an alternative complement pathway inhibitor for IgA nephropathy. Kidney Int. 2023. PMID: 37914086. doi:10.1016/j.kint.2023.09.027

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。